These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

353 related items for PubMed ID: 20303948

  • 21. L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model.
    Ando K, Inoue T, Itoh T.
    Pharmacol Biochem Behav; 2014 Dec; 127():62-9. PubMed ID: 25449794
    [Abstract] [Full Text] [Related]

  • 22. Fatty acid amide hydrolase (FAAH) inhibition reduces L-3,4-dihydroxyphenylalanine-induced hyperactivity in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned non-human primate model of Parkinson's disease.
    Johnston TH, Huot P, Fox SH, Wakefield JD, Sykes KA, Bartolini WP, Milne GT, Pearson JP, Brotchie JM.
    J Pharmacol Exp Ther; 2011 Feb; 336(2):423-30. PubMed ID: 20966038
    [Abstract] [Full Text] [Related]

  • 23. [The combined treatment of Parkinson's disease with L-dopa plus decarboxylase inhibitors (carbidopa, benserazide) (author's transl)].
    Podiwinsky F, Mentasti M, Riederer P, Birkmayer W.
    Wien Klin Wochenschr; 1979 May 11; 91(10):332-7. PubMed ID: 452602
    [Abstract] [Full Text] [Related]

  • 24. The administration of entacapone prevents L-dopa-induced dyskinesia when added to dopamine agonist therapy in MPTP-treated primates.
    Zubair M, Jackson MJ, Tayarani-Binazir K, Stockwell KA, Smith LA, Rose S, Olanow W, Jenner P.
    Exp Neurol; 2007 Dec 11; 208(2):177-84. PubMed ID: 17935716
    [Abstract] [Full Text] [Related]

  • 25. Locomotor response to L-DOPA in reserpine-treated rats following central inhibition of aromatic L-amino acid decarboxylase: further evidence for non-dopaminergic actions of L-DOPA and its metabolites.
    Alachkar A, Brotchie JM, Jones OT.
    Neurosci Res; 2010 Sep 11; 68(1):44-50. PubMed ID: 20542064
    [Abstract] [Full Text] [Related]

  • 26. Pramipexole combined with levodopa improves motor function but reduces dyskinesia in MPTP-treated common marmosets.
    Tayarani-Binazir KA, Jackson MJ, Rose S, Olanow CW, Jenner P.
    Mov Disord; 2010 Feb 15; 25(3):377-84. PubMed ID: 20108359
    [Abstract] [Full Text] [Related]

  • 27. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A, Li Q, Gardoni F, Marcello E, Qin C, Carlsson T, Kirik D, Di Luca M, Björklund A, Bezard E, Carta M.
    Brain; 2008 Dec 15; 131(Pt 12):3380-94. PubMed ID: 18952677
    [Abstract] [Full Text] [Related]

  • 28. Continuous delivery of ropinirole reverses motor deficits without dyskinesia induction in MPTP-treated common marmosets.
    Stockwell KA, Virley DJ, Perren M, Iravani MM, Jackson MJ, Rose S, Jenner P.
    Exp Neurol; 2008 May 15; 211(1):172-9. PubMed ID: 18321484
    [Abstract] [Full Text] [Related]

  • 29. Patient benefits of l-dopa and a decarboxylase inhibitor in the treatment of Parkinson's disease in elderly patients.
    Admani AK, Verma S, Cordingley GJ, Harris RI.
    Pharmatherapeutica; 1985 May 15; 4(2):132-40. PubMed ID: 4059292
    [Abstract] [Full Text] [Related]

  • 30. [A model of Parkinson's disease: effect of L-dopa therapy on movement parameters and electromyographic activity in monkeys treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
    Doudet D, Gross C, Lebrun-Grandié P, Bioulac B.
    C R Seances Soc Biol Fil; 1985 May 15; 179(1):85-97. PubMed ID: 3161601
    [Abstract] [Full Text] [Related]

  • 31. [A new levodopa benserazide preparation for Parkinson's disease with motor fluctuations refractory to standard L-dopa].
    Fernández Pardal MM, Gatto E, Micheli F, Casas Parera I, Diaz S.
    Medicina (B Aires); 1991 May 15; 51(6):561-7. PubMed ID: 7476112
    [Abstract] [Full Text] [Related]

  • 32. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets.
    Jackson MJ, Al-Barghouthy G, Pearce RK, Smith L, Hagan JJ, Jenner P.
    Pharmacol Biochem Behav; 2004 Nov 15; 79(3):391-400. PubMed ID: 15582011
    [Abstract] [Full Text] [Related]

  • 33. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys.
    Grégoire L, Samadi P, Graham J, Bédard PJ, Bartoszyk GD, Di Paolo T.
    Parkinsonism Relat Disord; 2009 Jul 15; 15(6):445-52. PubMed ID: 19196540
    [Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques.
    Visanji NP, Fox SH, Johnston TH, Millan MJ, Brotchie JM.
    J Pharmacol Exp Ther; 2009 Jan 15; 328(1):276-83. PubMed ID: 18955589
    [Abstract] [Full Text] [Related]

  • 36. Unilateral pallidotomy in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated common marmosets exhibiting levodopa-induced dyskinesia.
    Iravani MM, Costa S, Al-Bargouthy G, Jackson MJ, Zeng BY, Kuoppamäki M, Obeso JA, Jenner P.
    Eur J Neurosci; 2005 Sep 15; 22(6):1305-18. PubMed ID: 16190886
    [Abstract] [Full Text] [Related]

  • 37. NB-355: a novel prodrug for L-DOPA with reduced risk for peak-dose dyskinesias in MPTP-treated squirrel monkeys.
    Tye SJ, Rupniak NM, Naruse T, Miyaji M, Iversen SD.
    Clin Neuropharmacol; 1989 Oct 15; 12(5):393-403. PubMed ID: 2611764
    [Abstract] [Full Text] [Related]

  • 38. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease.
    Fox SH, Henry B, Hill M, Crossman A, Brotchie J.
    Mov Disord; 2002 Nov 15; 17(6):1180-7. PubMed ID: 12465055
    [Abstract] [Full Text] [Related]

  • 39. Levetiracetam potentiates the antidyskinetic action of amantadine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate model of Parkinson's disease.
    Hill MP, Ravenscroft P, Bezard E, Crossman AR, Brotchie JM, Michel A, Grimée R, Klitgaard H.
    J Pharmacol Exp Ther; 2004 Jul 15; 310(1):386-94. PubMed ID: 15004218
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.